Company Profile

Acura Pharmaceuticals Inc
Profile last edited on: 12/14/2023      CAGE: 6ZMA1      UEI: QBFKBYCMM2Z2

Business Identifier: Abuse-resistant products for pain and nasal congestion
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

616 N North Court Suite 120
Palatine, IL 60067
   (847) 705-7709
Location: Multiple
Congr. District: 05
County: Cook

Public Profile

Acura Pharmaceuticals, Inc is a specialty pharmaceutical companyy involved in development of products to address medication abuse and misuse utilizing its proprietary Aversion and Impede technologies. The company offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets for the use as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. It has seven additional opioid products, including hydrocodone bitartrate/acetaminophen, hydromorphone HCl, methadone HCl, morphine sulfate, oxycodone HCl/acetaminophen, oxymorphone HCl, and tramadol HCl tablets utilizing Aversion technology in various stages of development. The company has collaboration and license agreements with Egalet US, Inc.; Egalet Ltd.; and Egalet Corporation to manufacture and commercialize Oxaydo products worldwide.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2014 1 NIH $299,694
Project Title: A Proposal To Develop A Self-Regulating Hydromorphone Tablet To Deter Excess Oral

Key People / Management

  Robert B Jones -- Chief Exec. Officer, Pres and Director

  Albert W Brzeczko -- VP of Technical Affairs

  Peter A Clemens -- Chief Financial Officer, Principal Accounting Officer, Sr. VP and Sec.

  James Emigh -- Vp, Corporate Development

  J Bradley Rivet -- VP of Marketing

  Robert A Seiser -- VP, Treasurer and Corp. Controller

Company News

There are no news available.